Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Conflicting evidence exists regarding lenalidomide's efficacy in myelofibrosis (MF).
• Lenalidomide is an immunomodulatory drug with potential anti-neoplastic effects.
• Myelofibrosis is a serious myeloproliferative neoplasm characterized by bone marrow fibrosis.

Purpose of the Study:

• To evaluate the efficacy of lenalidomide in MF patients within an Austrian named patient program.
• To assess lenalidomide's effectiveness in a real-world, non-study patient cohort.

Main Methods:

• Retrospective analysis of 22 MF patients treated with lenalidomide across 7 Austrian centers.
• Patients were characterized by age, MF subtype (primary, post-PV, post-ET), and risk stratification (DIPSS).
• Overall response rate (ORR) was assessed using International Working Group (IWG) criteria.

Main Results:

• The overall response rate (ORR) was 12.5% according to IWG criteria.
• Median patient age was 68 years; 13 had primary MF, 8 post-PV MF, and 1 post-ET MF.
• All patients were classified as intermediate-2 or high-risk by DIPSS; approximately one-third received prior therapies.

Conclusions:

• Lenalidomide demonstrated moderate efficacy in this cohort of Austrian MF patients.
• Disease stage and patient risk profile (DIPSS intermediate-2/high-risk) appear to be limiting factors for lenalidomide's effectiveness.
• Further research may be needed to identify optimal patient selection for lenalidomide therapy in MF.